New drug combo shows promise for recurrent ovarian cancer
NCT ID NCT04034927
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This phase II trial tests whether adding the immunotherapy tremelimumab to the PARP inhibitor olaparib works better than olaparib alone for women with platinum-sensitive recurrent ovarian, fallopian tube, or peritoneal cancer. About 61 participants will receive either olaparib alone or olaparib plus tremelimumab. The study measures how long the cancer stays under control and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- olaparib and tremelimumab
- What this could lead to
- If successful, this combination could offer a more effective treatment option for women with recurrent ovarian cancer that responds to platinum-based therapy.
- What could go wrong
- This is a small, early-phase trial (61 participants) testing safety and effectiveness. The combination may cause more side effects and may not improve outcomes over olaparib alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE ENDOMETRIOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Augusta University Medical Center
Augusta, Georgia, 30912, United States
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Hartford Hospital
Hartford, Connecticut, 06102, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio, 44122, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87106, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Women and Infants Hospital
Providence, Rhode Island, 02905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
- New targeted therapy shows promise for Tough-to-Treat ovarian cancer
- Engineered immune cells target Hard-to-Treat ovarian cancer
- New combo therapy aims to control ovarian cancer and reduce painful fluid buildup